Ask AI
ProCE Banner Activity

Community Practice Grand Rounds: A Multidisciplinary Framework for Integrating HER2- and TROP-2–Directed ADCs Into Personalized Management of NSCLC

Slideset

These downloadable slides examine the evolving role of HER2- and TROP-2–directed antibody–drug conjugates (ADCs) in the personalized management of non-small-cell lung cancer (NSCLC). Findings from the DESTINY-Lung, TROPION-Lung, OptiTROP-Lung, and EVOKE clinical trials provide insights into the efficacy, safety, and evolving roles of approved and investigational ADCs, including trastuzumab deruxtecan, datopotamab deruxtecan, sacituzumab govitecan, and sacituzumab tirumotecan, in the treatment of NSCLC. The slides highlight the clinical implications of HER2 mutations and overexpression, EGFR mutation status, and emerging TROP-2 biomarkers for treatment selection and sequencing, as well as considerations related to prior therapy, CNS metastases, and evolving HER2-targeted treatment options. Evidence-based strategies for preventing, recognizing, and managing ADC-associated toxicities, including interstitial lung disease/pneumonitis, stomatitis, ocular toxicity, and nausea and vomiting, are also addressed, emphasizing multidisciplinary care coordination, individualized risk–benefit assessment, and clinical trial referral to optimize patient outcomes.

Released: November 16, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

This activity is supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Target Audience

This activity is intended for community medical oncologists, nurse practitioners, physician associates, nurses, pharmacists, and other healthcare professionals caring for patients with NSCLC.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Differentiate HER2 mutation, HER2 tyrosine kinase domain mutation, HER2 IHC 3+ overexpression, EGFR mutation status, and investigational TROP2-NMR/QCS biomarker status to guide appropriate selection of approved or investigational HER2- and TROP-2–directed ADC strategies in NSCLC

  • Select and sequence HER2-directed and TROP-2–directed ADCs for appropriate patients with NSCLC, with consideration for prior therapy, biomarker status, CNS involvement, performance status, comorbidities, toxicity risks, patient goals, guideline recommendations, and clinical-trial availability

  • Implement multidisciplinary workflows to prevent, recognize, grade, and manage key ADC-associated adverse events, including ILD/pneumonitis, stomatitis/oral mucositis, ocular toxicity, nausea/vomiting, and myelosuppression

  • Identify patients with NSCLC who should be considered for clinical trials evaluating HER2- or TROP-2–directed ADCs, ADC combinations, and biomarker-selected strategies, and apply practical approaches to referral from community practice